BR112022019609A2 - Células geneticamente modificadas enriquecidas com mitocôndrias e usos das mesmas - Google Patents

Células geneticamente modificadas enriquecidas com mitocôndrias e usos das mesmas

Info

Publication number
BR112022019609A2
BR112022019609A2 BR112022019609A BR112022019609A BR112022019609A2 BR 112022019609 A2 BR112022019609 A2 BR 112022019609A2 BR 112022019609 A BR112022019609 A BR 112022019609A BR 112022019609 A BR112022019609 A BR 112022019609A BR 112022019609 A2 BR112022019609 A2 BR 112022019609A2
Authority
BR
Brazil
Prior art keywords
mitochondria
geneticly
modified cells
enriched
cells enriched
Prior art date
Application number
BR112022019609A
Other languages
English (en)
Inventor
Yivgi-Ohana Natalie
Sher Noa
Blumkin Moriya
Jacoby Elad
Original Assignee
Minovia Therapeutics Ltd
Tel Hashomer Medical Res Infrastructure & Services Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minovia Therapeutics Ltd, Tel Hashomer Medical Res Infrastructure & Services Ltd filed Critical Minovia Therapeutics Ltd
Publication of BR112022019609A2 publication Critical patent/BR112022019609A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464411—Immunoglobulin superfamily
    • A61K39/464412—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/02—Coculture with; Conditioned medium produced by embryonic cells
    • C12N2502/025—Coculture with; Conditioned medium produced by embryonic cells extra-embryonic cells, e.g. amniotic epithelium, placental cells, Wharton's jelly
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Reproductive Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)

Abstract

CÉLULAS GENETICAMENTE MODIFICADAS ENRIQUECIDAS COM MITOCÔNDRIAS E USOS DAS MESMAS. A presente invenção refere-se as células enriquecidas com mitocôndrias que são úteis para o tratamento de doenças e distúrbios. São divulgadas composições farmacêuticas de células T geneticamente modificadas mitocondrialmente enriquecidas e métodos de tratamento usando células T geneticamente modificadas mitocondrialmente enriquecidas.
BR112022019609A 2020-03-31 2021-03-30 Células geneticamente modificadas enriquecidas com mitocôndrias e usos das mesmas BR112022019609A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063003184P 2020-03-31 2020-03-31
PCT/IL2021/050358 WO2021199040A1 (en) 2020-03-31 2021-03-30 Mitochondria-enriched genetically engineered cells and uses thereof

Publications (1)

Publication Number Publication Date
BR112022019609A2 true BR112022019609A2 (pt) 2022-11-29

Family

ID=77930147

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022019609A BR112022019609A2 (pt) 2020-03-31 2021-03-30 Células geneticamente modificadas enriquecidas com mitocôndrias e usos das mesmas

Country Status (12)

Country Link
US (1) US20230123731A1 (pt)
EP (1) EP4125948A4 (pt)
JP (1) JP2023520502A (pt)
KR (1) KR20230017163A (pt)
CN (1) CN115605220A (pt)
AU (1) AU2021249553A1 (pt)
BR (1) BR112022019609A2 (pt)
CA (1) CA3172402A1 (pt)
CO (1) CO2022015278A2 (pt)
IL (1) IL296735A (pt)
MX (1) MX2022012157A (pt)
WO (1) WO2021199040A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013035101A1 (en) 2011-09-11 2013-03-14 Minovia Therapeutics Ltd. Compositions of functional mitochondria and uses thereof
JP7458368B2 (ja) 2018-07-22 2024-03-29 ミノヴィア セラピューティクス リミテッド 筋疾患のミトコンドリア増強療法
KR20230135577A (ko) * 2021-01-25 2023-09-25 미노비아 테라퓨틱스 리미티드 미토콘드리아-풍부화된 세포의 식별
WO2024030441A1 (en) * 2022-08-02 2024-02-08 National University Corporation Hokkaido University Methods of improving cellular therapy with organelle complexes

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3102609A4 (en) * 2014-02-04 2017-08-23 The United States of America, as represented by The Secretary, Department of Health and Human Services Methods for producing autologous t cells useful to treat b cell malignancies and other cancers and compositions thereof
EP3169773B1 (en) * 2014-07-15 2023-07-12 Juno Therapeutics, Inc. Engineered cells for adoptive cell therapy
IL299482A (en) * 2015-02-26 2023-02-01 Minovia Therapeutics Ltd Mammalian cells are enriched in active mitochondria
US20210252075A1 (en) * 2018-07-22 2021-08-19 Minovia Therapeutics Ltd. Mitochondrial augmentation therapy of liver diseases
WO2020036973A1 (en) * 2018-08-14 2020-02-20 Imel Biotherapeutics, Inc. Methods and compositions for treating mitochondrial disease or disorders and heteroplasmy

Also Published As

Publication number Publication date
CA3172402A1 (en) 2021-10-07
EP4125948A4 (en) 2024-05-29
JP2023520502A (ja) 2023-05-17
EP4125948A1 (en) 2023-02-08
MX2022012157A (es) 2023-02-15
CN115605220A (zh) 2023-01-13
CO2022015278A2 (es) 2022-10-31
US20230123731A1 (en) 2023-04-20
KR20230017163A (ko) 2023-02-03
AU2021249553A1 (en) 2022-11-03
IL296735A (en) 2022-11-01
WO2021199040A1 (en) 2021-10-07

Similar Documents

Publication Publication Date Title
BR112022019609A2 (pt) Células geneticamente modificadas enriquecidas com mitocôndrias e usos das mesmas
BR112021005769A2 (pt) proteínas de ligação a dll3 e métodos de uso
ECSP19043710A (es) Composiciones de aminoácidos y métodos de tratamiento de enfermedades hepáticas
BR112019005595A2 (pt) compostos e métodos para modulação de ido e tdo, e indicações para os mesmos
CR11817A (es) Anticuerpos anti-factor d humanizados y sus usos
CO2018005361A2 (es) Formulaciones inyectables de toxina botulínica y sus métodos de uso que poseen efecto terapéutico o cosmético de larga duración
CR20110509A (es) Composicion farmaceutica
AR063760A1 (es) Anticuerpos anti-factor d humanizados y usos de los mismos
BR112017012377A2 (pt) conjugados anticorpo-fármaco com inibidores de bcl-xl permeáveis à célula
DOP2011000114A (es) “compuestos de 9h-purin-6-aminoalquilo que expanden las celulas madre hematopoyeticas
CL2021000207A1 (es) Nuevas proteínas de fusión específicas para cd137 y pd-l1
BR112018005861A2 (pt) derivados de ácido oleanólico modificado com c4 para a inibição de il-17 e outros usos
CL2023000371A1 (es) Composiciones y métodos para inhibir la expresión de plp1.
BR112013001753A2 (pt) método para preparar uma composição d einter-alfa-inibidor (iaip) eriquecida de plasma, solução aquosa de iaip, e, método para tratar uma doença ou distúrbio associado com disfunção de iaip e associado com atividadede protease de serina no plasma aumentada.
GT201200252A (es) Anticuerpos monoclonales optimizados contra el inhibidor de la vía del factor tisular (tfpi)
BR112022013236A2 (pt) Anticorpos anti-cd73 e usos dos mesmos
BR112018067946A8 (pt) Formulações tópicas contendo ciclosporina e usos das mesmas
BR112017010599A2 (pt) análogos de ureia ligada substituída como moduladores sirtuin
BR112021019558A2 (pt) Composições e métodos para preparar composições de células t e usos dos mesmos
BR112021023048A2 (pt) Moléculas de ligação a cd19 e usos das mesmas
BR112023001957A2 (pt) Composições e métodos para inibir expressão de lpa
DOP2023000223A (es) Composiciones y métodos para inhibir cetohexoquinasa (khk)
BR112019007543A2 (pt) inibidores de ácido alfa-amino-beta-carboximuconico semialdeido decarboxilase
BR112018017174A2 (pt) conjugados de aminoácido e peptídeo e processo de conjugação
BR112016008086A2 (pt) Glicoproteínas recombinantes e usos das mesmas

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing